Company Profile
CEO
Mr. Daniel Patrick O'Day(Chairman & CEO)
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
17.0K
Beta
0.33
Forward P/E
13.5
52W High
$157.29
52W Low
$104.46
Profit Margin
31.0%
Operating Margin
39.3%
Return on Equity
43.4%
Revenue Growth
4.4%
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV...
Valuation
Market Cap$159.05B
P/E (TTM)17.44
P/S (TTM)5.71
EV/EBITDA--
Cash Flow
FCF Yield+6.1%
SBC Adj. FCF Yield+5.6%
SBC Impact9.0%
Margins & Growth
Profit Margin29.0%
Operating Margin37.2%
Revenue YoY4.4%
Earnings YoY53.7%
Balance
Cash$7.63B
Debt$22.17B
Net Cash$-14.55B
Dividend
Dividend Yield2.62%
Payout Ratio51.5%
Quarterly Payout$1.04B